Latest Information Update: 24 Mar 2009
At a glance
- Originator Eli Lilly
- Class Neuropsychotherapeutics
- Mechanism of Action Adrenergic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mood disorders
Most Recent Events
- 24 Mar 2009 Discontinued - Phase-I for Affective disorders in USA (PO)